Viatris inks $1.65B Pacira buyout to build non-opioid pain therapy business

Viatris agreed to buy Pacira BioSciences for $1.65B to expand its non-opioid pain therapy business. Pacira's drugs, Exparel and Zilretta, had combined sales of $708M in the last year. Viatris aims to generate revenue and cost synergies, with peak sales of FAM projected at $500M. The deal is subject to regulatory approval and expected to close by year-end.

Original reporting
Published Oct 9, 2026, 11:58 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 9, 2026, 12:51 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Viatris inks $1.65B Pacira buyout to build non-opioid pain therapy business — source image
Decision brief

The 30-second read

$VTRSBullishHigh
01

Why it matters

The acquisition provides immediate revenue from Exparel and Zilretta and positions Viatris for future growth with its fast‑acting meloxicam formulation.

02

Market read

The deal creates a larger non‑opioid pain player, likely moving both stocks and influencing sector sentiment.

03

What to watch

Regulatory timing of Viatris' own non‑opioid filing (PDUFA deadline Dec 27) could affect integration risk.

Relevance 9/10Novelty 9/10Timing: today

Background

Viatris, created by Pfizer in 2020, seeks to broaden its pain portfolio amid FDA review of its own non‑opioid candidate.

Company-level read

Ticker impact

$VTRSBullishHigh confidence
Context

Viatris announced a $1.65 billion cash acquisition of Pacira BioSciences, creating a non‑opioid pain franchise.

Expected impact

likely upward pressure as the market prices in the acquisition premium and growth potential.

Evidence & confidence

The cash premium of $36.50 per share versus the prior close of $25.20 signals a strong valuation uplift and immediate upside.

Market effects

Strengthens the non‑opioid pain therapy segment and may spur consolidation activity in specialty pharma.

U.S. market impact as both companies are U.S.-listed; limited global effect.

Highlights growing focus on opioid‑alternatives, relevant to global healthcare investors.

Counterpoint

Deal premium may be excessive if Pacira faces upcoming generic competition, potentially limiting upside.

Key entities

  • Viatris

    US‑listed pharmaceutical company (ticker VTRS).

  • Pacira BioSciences

    US‑listed specialty pharma (ticker PACB).

Related articles

$VTRSMedAI 8/10

Viatris completes $1.6B acquisition

Viatris Inc. (VTRS) completed its $1.65B acquisition of Pacira BioSciences Inc. (PCRX), a developer of nonopioid pain treatments. The deal aims to strengthen Viatris's U.S. innovative medicines business and establish leadership in non-opioid pain management, according to the company.

$VTRSMedAI 8/10

Viatris Completes Acquisition of Pacira BioSciences for $36.50 Per Share, Expanding Non-Opioid Pain Management Portfolio

Viatris (VTRS) completed its acquisition of Pacira BioSciences (PCRX) for $36.50 per share, expanding its non-opioid pain management portfolio. Pacira is expected to contribute $90M-$100M in revenue for the remainder of 2026. The deal strengthens Viatris' U.S. innovative medicines business and positions it in the non-opioid pain management market.

$VTRSMedAI 9/10

Viatris Closes $1.65 Billion Pacira Deal for Non-Opioid Pain Medicines

Viatris (VTRS) completed its $1.65 billion acquisition of Pacira BioSciences (PCRX) at $36.50 per share. The deal adds two pain treatments, EXPAREL and ZILRETTA, with expected revenue of $90M-$100M for the rest of 2026. Pacira reported $746M in revenue and $177M in adjusted EBITDA for the year ending June 2026. Viatris plans to expand the products' reach and advance Pacira's clinical-stage assets.